Exploring the EPO/EPOR-βCR/TLR9 pathways in sepsis-associated encephalopathy: Therapeutic implications of EPO and HBSP
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2025.116053 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Ping Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Nanchang University, Jiang Xi Medical College, Nanchang University, Nanchang 330003, Jiangxi, China. Hauptthemen laut MEDLINE: Erythropoietin, Sepsis-Associated Encephalopathy, Toll-Like Receptor 9, Receptors, Erythropoietin. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Health Commission of Hubei Province.
Themen: Sepsis
Abstract (Originalsprache)
OBJECTIVE: Delirium is a prominent clinical manifestation of sepsis-associated encephalopathy (SAE) and is closely linked to increased mortality and adverse outcomes. Erythropoietin (EPO), traditionally used for treating anemia, is increasingly recognized for its non-hematopoietic tissue-protective effects. However, the relationship between EPO and the development of SAE, as well as the underlying mechanisms, remain unclear. METHODS: First, a retrospective analysis of clinical data from 150 septic patients was conducted to assess the correlation between serum EPO levels and delirium incidence and 28-day mortality. Second, the effects of EPO and its derivative helix B surface peptide (HBSP) on neuroinflammation and neuroplasticity were evaluated in vivo and in vitro. RESULTS: Elevated serum EPO levels were identified as an independent risk factor for delirium. Animal studies demonstrated a positive correlation between elevated EPO and the severity of sepsis and SAE. Mechanistically, high-dose EPO exacerbated systemic inflammation, disrupted the blood-brain barrier, and impaired cognition in septic rats. Conversely, treatment with low-dose EPO or HBSP upregulated the expression of βCR and TLR9, inhibiting microglia M1 polarization while promoting M2 polarization, ultimately attenuating neuroinflammation and neuronal apoptosis. However, this neuroprotective effect was abolished by βCR knockdown or TLR9 agonist ODN1826. CONCLUSION: In SAE, EPO exhibits a complex, concentration-dependent role: moderate EPO elevation can limit inflammatory cascades, while high levels may exacerbate inflammation. Mechanistically, activation of microglial EPOR-βCR inhibits the TLR9/MyD88/NF-κB signaling pathway. These findings offer new insights into the nuanced role of EPO in SAE pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital of Nanchang University, Jiang Xi Medical College, Nanchang University, Nanchang 330003, Jiangxi, China.
- Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan 432000, Hubei, China.
- Affiliated Rehabilitation Hospital, Jiang Xi Medical College, Nanchang University, Nanchang 330003, Jiangxi, China.
- The First Affiliated Hospital of Nanchang University, Jiang Xi Medical College, Nanchang University, Nanchang 330003, Jiangxi, China; Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan 43…
Förderung
- Health Commission of Hubei Province
Zitieren
APA
Hu, P., Shen, W., Zhou, Q., Yao, H., & Yao, P. (2026). Exploring the EPO/EPOR-βCR/TLR9 pathways in sepsis-associated encephalopathy: Therapeutic implications of EPO and HBSP. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.116053
Vancouver
Hu P, Shen W, Zhou Q, Yao H, Yao P. Exploring the EPO/EPOR-βCR/TLR9 pathways in sepsis-associated encephalopathy: Therapeutic implications of EPO and HBSP. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2025.116053
BibTeX
@article{Hu2026,
author = {Hu, Ping and Shen, Wei and Zhou, Qianhui and Yao, Hao and Yao, Peng},
title = {Exploring the EPO/EPOR-βCR/TLR9 pathways in sepsis-associated encephalopathy: Therapeutic implications of EPO and HBSP},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2025.116053}
}
EUVIMED